Phaseline

Companies › Opus Genetics

Opus Genetics: clinical trials, targets and expected readouts

4 active drug programs in 5 registered trials: 4 Phase 1, 1 Phase 3; Ophthalmology, Metabolic and endocrine; next expected readout Aug 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Phentolamine Ophthalmic Solution 0.75%
Non-selective alpha-1 and alpha-2 adrenergic antagonist
ADRA1A, ADRA1B, ADRA1D, ADRA2APhase 3Vision Loss Night; Insulin ResistanceAug 2027
OPGx-001
AAV8 vector expressing human LCA5 gene
LCA5Phase 1LCA5Jun 2028
OPGx-BEST1
Gene therapy delivering BEST1 gene via subretinal injection
BEST1Phase 1ARBAug 2030
OPGx-RDH12
Gene therapy delivering functional RDH12 gene to retinal cells
RDH12Phase 1Leber Congenital AmaurosisDec 2032

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03318094Phentolamine Ophthalmic Solution 0.75%Phase 1Insulin ResistanceMetabolic and endocrineNov 2026
NCT07140783Phentolamine Ophthalmic Solution 0.75%Phase 3Vision Loss NightOphthalmologyAug 2027
NCT05616793OPGx-001Phase 1LCA5OphthalmologyJun 2028
NCT07185256OPGx-BEST1Phase 1ARBOphthalmologyAug 2030
NCT07681778OPGx-RDH12Phase 1Leber Congenital AmaurosisOphthalmologyDec 2032

From the company's SEC filings

Cash of $89m on 2026-06-30; operating cash outflow about $50m a year; runway about 21 months at that burn, to Apr 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 5 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

LCA5 (1) BEST1 (1) RDH12 (1) ADRA1A (1) ADRA1B (1) ADRA1D (1) ADRA2A (1)

Companies with the same targets

Santen SAS Berlin-Chemie AG Menarini Group Applied Biology ARS Pharmaceuticals

Companies built like this

ProQR Therapeutics Ocugen Kiora Pharmaceuticals Laboratoires Thea Alcon Research

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.